These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23532750)

  • 1. Movement disorders in patients with schizophrenia and a history of substance abuse.
    Hansen LK; Nausheen B; Hart D; Kingdon D
    Hum Psychopharmacol; 2013 Mar; 28(2):192-7. PubMed ID: 23532750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.
    Miller DD; McEvoy JP; Davis SM; Caroff SN; Saltz BL; Chakos MH; Swartz MS; Keefe RS; Rosenheck RA; Stroup TS; Lieberman JA
    Schizophr Res; 2005 Dec; 80(1):33-43. PubMed ID: 16171976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.
    Zhornitsky S; Stip E; Pampoulova T; Rizkallah E; Lipp O; Bentaleb LA; Chiasson JP; Potvin S
    Mov Disord; 2010 Oct; 25(13):2188-94. PubMed ID: 20669315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.
    Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia.
    Maat A; Fouwels A; de Haan L
    Psychopharmacol Bull; 2008; 41(3):5-10. PubMed ID: 18779773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.
    Gebhardt S; Härtling F; Hanke M; Mittendorf M; Theisen FM; Wolf-Ostermann K; Grant P; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2006 Oct; 15(7):371-82. PubMed ID: 16648965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
    Dufresne RL; Wagner RL
    J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.
    Ryu S; Yoo JH; Kim JH; Choi JS; Baek JH; Ha K; Kwon JS; Hong KS
    J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.
    Cortese L; Caligiuri MP; Williams R; Schieldrop P; Manchanda R; Malla A; Harricharan R
    J Clin Psychopharmacol; 2008 Feb; 28(1):69-73. PubMed ID: 18204344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use.
    Lévy E; Margolese HC; Annable L; Chouinard G
    Can J Psychiatry; 2004 Jun; 49(6):398-402. PubMed ID: 15283536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR
    Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.
    Kim JH; Jung HY; Kang UG; Jeong SH; Ahn YM; Byun HJ; Ha KS; Kim YS
    Mov Disord; 2002 Nov; 17(6):1354-9. PubMed ID: 12465082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Akathisia: clinical phenomenology and relationship to tardive dyskinesia.
    Kahn EM; Munetz MR; Davies MA; Schulz SC
    Compr Psychiatry; 1992; 33(4):233-6. PubMed ID: 1353716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.